Strides Pharma Science Limited — Important, 17-03-2026: Arrangements for strategic, technical, manufacturing, or marketing tie up

Strides Pharma acquires and in-licenses multiple generic brands from Sandoz for an upfront consideration of approximately 99.6 Cr. This move strengthens Strides' Africa business, aiming for a top-five market position in Sub-Saharan Africa. The portfolio includes products with individual annual sales exceeding 8.3 Cr.